{"id":"cdk-4-6-inhibitors","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Neutropenia"},{"rate":"30-50","effect":"Leukopenia"},{"rate":"20-30","effect":"Anemia"},{"rate":"20-30","effect":"Nausea"},{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Diarrhea"},{"rate":"10-20","effect":"Vomiting"},{"rate":"10-20","effect":"Stomatitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting CDK4/6 activity, these drugs prevent cancer cells from progressing from the G1 phase into S phase of the cell cycle, effectively stopping tumor cell proliferation. This mechanism is particularly effective in hormone receptor-positive breast cancers that depend on cyclin D-CDK4/6 signaling. CDK4/6 inhibitors are typically used in combination with endocrine therapy to enhance anti-tumor activity.","oneSentence":"CDK 4/6 inhibitors block cyclin-dependent kinases 4 and 6, which prevents phosphorylation of the retinoblastoma protein and halts cell cycle progression at the G1/S checkpoint.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:43.025Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (in combination with endocrine therapy)"},{"name":"Hormone receptor-positive, HER2-negative early breast cancer (adjuvant setting, in combination with endocrine therapy)"}]},"trialDetails":[{"nctId":"NCT07498413","phase":"","title":"Epidemiology and Treatment of HR+/HER2- Breast Cancer in England","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-06-08","conditions":"Breast Cancer","enrollment":218677},{"nctId":"NCT07492641","phase":"PHASE3","title":"BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease","status":"NOT_YET_RECRUITING","sponsor":"BeOne Medicines","startDate":"2026-05-11","conditions":"HR+/HER2- Breast Cancer","enrollment":1056},{"nctId":"NCT06994377","phase":"","title":"Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy","status":"RECRUITING","sponsor":"European Institute of Oncology","startDate":"2025-06-25","conditions":"Metastatic Breast Cancer","enrollment":1000},{"nctId":"NCT07227233","phase":"PHASE2","title":"Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2026-04","conditions":"Breast Cancer","enrollment":105},{"nctId":"NCT07252726","phase":"PHASE4","title":"Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2026-02-02","conditions":"Metastatic Breast Cancer, Metastatic Prostate Cancer","enrollment":50},{"nctId":"NCT03697577","phase":"","title":"CDK and Body Composition Study","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2019-01-08","conditions":"Breast Cancer","enrollment":30},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT04968964","phase":"NA","title":"Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-03-07","conditions":"Breast Cancer, Cancer of the Breast","enrollment":55},{"nctId":"NCT06849947","phase":"PHASE2","title":"Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Yeon Hee Park","startDate":"2026-02-01","conditions":"Breast Cancer Metastatic","enrollment":272},{"nctId":"NCT06851442","phase":"PHASE1, PHASE2","title":"Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-05-16","conditions":"Breast Cancer","enrollment":8},{"nctId":"NCT04010357","phase":"PHASE2","title":"Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2020-01-13","conditions":"Small-cell Lung Cancer, Large Cell Neuroendocrine Carcinoma of the Lung, Extrapulmonary Small Cell Carcinoma","enrollment":14},{"nctId":"NCT05935748","phase":"PHASE2","title":"Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)","status":"TERMINATED","sponsor":"NiKang Therapeutics, Inc.","startDate":"2023-07-28","conditions":"ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer","enrollment":18},{"nctId":"NCT07223476","phase":"","title":"Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in Portugal","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-03-29","conditions":"Breast Cancer","enrollment":1926},{"nctId":"NCT07213206","phase":"PHASE3","title":"CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-10-07","conditions":"Breast Cancer","enrollment":1500},{"nctId":"NCT03959891","phase":"PHASE1","title":"AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2019-05-30","conditions":"Breast Cancer","enrollment":77},{"nctId":"NCT03425838","phase":"PHASE3","title":"Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Borstkanker Onderzoek Groep","startDate":"2017-11-09","conditions":"Breast Neoplasm Female","enrollment":1050},{"nctId":"NCT05582499","phase":"PHASE2","title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-01","conditions":"Breast Neoplasm, Breast Cancer, Breast Tumors","enrollment":716},{"nctId":"NCT03439735","phase":"PHASE2","title":"Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-07-20","conditions":"Breast Cancer","enrollment":45},{"nctId":"NCT05173103","phase":"","title":"Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer","status":"COMPLETED","sponsor":"University of Milano Bicocca","startDate":"2021-09-24","conditions":"Advanced Breast Cancer, Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer","enrollment":254},{"nctId":"NCT07021911","phase":"","title":"Concomitant Radiotherapy and New Drugs in Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Campus Bio-Medico","startDate":"2023-05-17","conditions":"Breast Cancer, Radiotherapy; Complications","enrollment":300},{"nctId":"NCT07008508","phase":"","title":"Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-05-15","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT06947811","phase":"PHASE1, PHASE2","title":"A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-06-09","conditions":"EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor","enrollment":71},{"nctId":"NCT06996093","phase":"PHASE3","title":"Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-06-02","conditions":"Breast Cancer","enrollment":2508},{"nctId":"NCT05190094","phase":"PHASE2","title":"Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.","status":"RECRUITING","sponsor":"International Cancer Research Group, United Arab Emirates","startDate":"2022-12-20","conditions":"Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer","enrollment":80},{"nctId":"NCT05621837","phase":"","title":"Quantifying Systemic Immunosuppression to Personalize Cancer Therapy","status":"RECRUITING","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2022-03-10","conditions":"Melanoma, Breast Cancer, Renal Cell Carcinoma","enrollment":1000},{"nctId":"NCT02040857","phase":"PHASE2","title":"Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-01","conditions":"Breast Cancer","enrollment":162},{"nctId":"NCT04022616","phase":"","title":"Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2010-06-04","conditions":"Breast Cancer","enrollment":99},{"nctId":"NCT04660435","phase":"","title":"To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer","status":"RECRUITING","sponsor":"Fondazione Sandro Pitigliani","startDate":"2020-09-01","conditions":"Metastatic Breast Cancer, ER Positive Breast Cancer, HER2-negative Breast Cancer","enrollment":150},{"nctId":"NCT06805812","phase":"","title":"Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","status":"RECRUITING","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2023-05-01","conditions":"Breast Adenocarcinoma, Breast Cancer Stage IV, Breast Cancer, Metastatic","enrollment":3500},{"nctId":"NCT06147232","phase":"PHASE2","title":"Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia","status":"NOT_YET_RECRUITING","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2025-02","conditions":"Nephropathy, Diabetic Nephropathies, Diabetes Mellitus, Type 1","enrollment":69},{"nctId":"NCT06044623","phase":"PHASE3","title":"Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients","status":"RECRUITING","sponsor":"Region Örebro County","startDate":"2024-04-01","conditions":"Metastatic Breast Cancer, Advanced Breast Cancer, Quality of Life","enrollment":495},{"nctId":"NCT06569459","phase":"PHASE2","title":"Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-07-09","conditions":"Esophageal Cancer","enrollment":60},{"nctId":"NCT06558084","phase":"","title":"Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-07-06","conditions":"Toxicity, Drug, Progression, Disease","enrollment":64},{"nctId":"NCT06481956","phase":"PHASE2","title":"T-DM1 Combined With CDK4/6 Inhibitor Ribociclib","status":"ENROLLING_BY_INVITATION","sponsor":"Zheng Yabing","startDate":"2023-10-25","conditions":"HER2-positive Advanced Breast Cancer","enrollment":40},{"nctId":"NCT06463626","phase":"","title":"Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - REVEAL Study","status":"COMPLETED","sponsor":"Novartis","startDate":"2020-04-06","conditions":"Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","enrollment":121},{"nctId":"NCT04738292","phase":"PHASE2","title":"Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2021-10-05","conditions":"ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer","enrollment":11},{"nctId":"NCT06367335","phase":"","title":"Characteristics and Predictors of Liver Injury in Cyclin-dependent Kinase Inhibitors 4/6 (CDK4/6)-Treated Patients With Advanced Breast Cancer","status":"COMPLETED","sponsor":"University of Milano Bicocca","startDate":"2022-06-01","conditions":"DILI","enrollment":128},{"nctId":"NCT05905341","phase":"PHASE1","title":"Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2024-01-15","conditions":"Breast Cancer, Ovarian Cancer, Liposarcoma","enrollment":""},{"nctId":"NCT04821570","phase":"","title":"To Assess Immunogenicity of Coronavirus Disease 2019 (COVID-19) Vaccine in Cancer Patients Receiving Cancer Treatment","status":"UNKNOWN","sponsor":"University of Kansas Medical Center","startDate":"2021-02-23","conditions":"Breast Cancer, Lung Cancer, Melanoma (Skin)","enrollment":500},{"nctId":"NCT05559528","phase":"","title":"BRaziLian outcomE for metAStatic breasT Cancer","status":"UNKNOWN","sponsor":"Hospital do Coracao","startDate":"2021-09-13","conditions":"Metastatic Breast Cancer, Breast Cancer Stage IV","enrollment":300},{"nctId":"NCT05191914","phase":"PHASE4","title":"Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors","status":"UNKNOWN","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2022-02-07","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT04585724","phase":"PHASE1","title":"Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases","status":"WITHDRAWN","sponsor":"Emory University","startDate":"2020-06-12","conditions":"Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain","enrollment":""},{"nctId":"NCT05051956","phase":"","title":"Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?","status":"UNKNOWN","sponsor":"Namik Kemal University","startDate":"2021-10-01","conditions":"Can the Geriatric Questionnaires Predict Adverse Effects in Geriatric Breast Cancer Patients Treated With Cyclin-dependent Kinase 4 and 6 Inhibitors","enrollment":140},{"nctId":"NCT04133207","phase":"","title":"Clinical Outcome and Toxicity Data in Patients With Advanced Breast Cancer Treated With CDK Inhibitors Combined With Endocrine Therapy","status":"COMPLETED","sponsor":"Hellenic Cooperative Oncology Group","startDate":"2019-01-01","conditions":"Breast Cancer Stage IV","enrollment":340},{"nctId":"NCT04474951","phase":"NA","title":"Food Supplements Based on Nettle and Peppermint to Control Signs and Symptoms Induced by Cancer Therapies","status":"UNKNOWN","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2019-06-20","conditions":"Breast Cancer, Gynecologic Cancer","enrollment":60},{"nctId":"NCT03195192","phase":"NA","title":"Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Side-Out Foundation","startDate":"2017-03-09","conditions":"Metastatic Breast Cancer","enrollment":28},{"nctId":"NCT03988114","phase":"PHASE4","title":"A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer","status":"WITHDRAWN","sponsor":"Eli Lilly and Company","startDate":"2019-09-16","conditions":"Metastatic Breast Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CDK 4/6 inhibitors","genericName":"CDK 4/6 inhibitors","companyName":"Region Örebro County","companyId":"region-rebro-county","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CDK 4/6 inhibitors block cyclin-dependent kinases 4 and 6, which prevents phosphorylation of the retinoblastoma protein and halts cell cycle progression at the G1/S checkpoint. Used for Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (in combination with endocrine therapy), Hormone receptor-positive, HER2-negative early breast cancer (adjuvant setting, in combination with endocrine therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}